 Stimulation of chemotaxis by chemotactic peptides |
| Accordingly, it is an object of this invention to provide a synthetic material having chemotactic ... |
|
| Biological material pre-fixation treatment |
| OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic ... |
|
| Diagnosis of Williams syndrome |
| OF THE INVENTION The present invention is directed to the determination that SVAS and Williams ... |
|
| Biological material pre-fixation treatment |
| OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic ... |
|
| Method for bonding or fusion of biological tissue and material |
| Biological materials are joined, repaired or fused by heating the material in proximity to a ... |
|
| Diagnosis and treatment of supravalvular aortic stenosis and Williams syndrome |
| OF THE INVENTION The present invention is directed to the determination that SVAS and Williams ... |
|
| Biological material pre-fixation treatment |
| OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic ... |
|
| Matrix substrate for a viable body tissue-derived prosthesis and method for making the same |
| OF THE INVENTION The present invention covers a process that thoroughly removes intact cells from ... |
|
| Barrier webs having bioactive surfaces |
| What is claimed is: 1. A bioactive substrate comprising: a support; and a bioactive surface thereon,... |
|
| Biopolymer foams for use in tissue repair and reconstruction |
| OF THE INVENTION The present invention features biopolymer foams, composite biopolymer foams, ... |
|
|
Leptospira rare outer membrane proteins
| Details |
Inventors: Haake, David A.; Shang, Ellen S.;
Assignee: The Regents of the University of California (Oakland, CA)
Primary Examiner: Swartz; Rodney P
Assistant Examiner:
Attorney, Agent or Firm: Gray Cary Ware & Freidenrich, LLP, Haile; Lisa A., Imbra; Richard J.
The present invention presents novel leptospiral membrane lipoproteins, LipL1 and LipL2, associated with pathogenic strains of Leptospira. LipL1 is of about 35 kDa, and LipL2 is of about 41 kDa. Also disclosed are the method for purifying these proteins from Leptospira, their nucleotide and amino acid sequences, the cloning of the genes encoding the proteins and their recombinant proteins, methods for producing antibodies to these proteins, the resulting antibodies. These proteins, their immunogenic fragments, and antibodies against them, are useful for inducing an immune response to pathogenic Leptospira as well as providing a diagnostic target for leptospirosis. |
|
DETAILED DESCRIPTION The present invention presents two novel leptospiral membrane proteins: LipL1 and LipL2.
In particular, these proteins are lipoproteins which are associated with pathogenic strains of Leptospira.
LipL1 is about 35 kDa, and LipL2 is about 41 kDa.
Also disclosed are the method for purifying these proteins from Leptospira, their nucleotide and amino acid sequences, the cloning of the genes encoding the proteins and their recombinant proteins, methods for producing antibodies to these proteins, and the resulting antibodies.
These proteins, their immunogenic fragments, and antibodies capable of binding to them, are useful for inducing an immune response to pathogenic Leptospira as well as providing a diagnostic target for leptospirosis.
|
| Related patents |
|
|
Interleukin-1 beta converting enzyme like apoptotic protease-6
Toward these ends, and others, it is an object of the present invention to provide polypeptides, inter alia, that have been identified as novel ICE LAP-6 by homology ...
|
|
|
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
What is claimed is: 1. A therapeutic composition comprising at least one angiogenesis inhibiting agent, which is an .alpha..sub.v.beta..sub.3 antagonist; and at least ...
|
|
|
Expressed sequence tags and encoded human proteins
The present invention relates to purified, isolated, or enriched 5' ESTs which include sequences derived from the authentic 5' ends of their corresponding mRNAs. The ...
|
|
|
C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
The invention claimed is: 1. An isolated PC-LECTIN protein comprising the amino acid sequence of SEQ ID NO. 2. 2. The PC-LECTIN protein of claim 1 which is soluble. 3. ...
|
|
|
Antibodies for use in determining hemoglobin A.sub.1c
It is accordingly an object of the present invention to provide a comparatively simple, inexpensive, reliable test for determining the long-term blood sugar level of a ...
|
|
|
Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives
OF THE INVENTION A hapten of the invention is substantially optically pure, and is particularly useful in an immunoassay for cotinine, a metabolite of nicotine. As used ...
|
|
|
Immunogens and the use thereof for obtaining antibodies against HBA.sub.1C
What is claimed is: 1. Composition of matter consisting essentially of polyclonal antibodies which specifically bind to HbA.sub.1c and which have less than 5.0% cross ...
|
|
|
Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
The present invention overcomes the above mentioned drawbacks and provides methods for treating drug abuse. Using therapeutic compositions, in particular hapten-carrier ...
|
|
|
Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
OF THE INVENTION The present invention is directed to methods for developing and utilizing antibodies with preferred specificity for phenylboronic acid complexes of ...
|
|
|
Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers
The invention claimed is: 1. An oral pharmaceutical formulation comprising phytosterols and isomers thereof, folic acid, cyanocobalamine, pyridoxine and dietetic ...
|
|
|
Drugs 
